Rise and shine, everyone, another day is on the way. Although, this will be an abbreviated session: we will be rolling in the sidewalks a bit early due to the holiday on this side of the pond. Already, it appears somewhat quiet, yes? Just the same, we intend to keep busy as we prepare for the days ahead and trust some of you will be doing the same. So please join us a for cup of stimulation as we dig in. Meanwhile, we do hope you enjoy the day off tomorrow. A day of rest once in a while is a good thing. See you soon...
How To Tell When A Company Fibs About Trial Results (The Street)
UK To Spend Less On Branded Drugs (Pharma Times)
J&J Recalls K-Y Liquibeads Vaginal Moisturizer (Dow Jones)
Botox May Help Multiple Sclerosis Tremors (Reuters)
J&J Seeks FDA OK For First Drug Against Resistant TB (Associated Press)
Glaxo Whistleblower Recalls Frustration (Tampa Bay Times)
After Roche Merger, Biotech Tail Wags Pharma Dog (Reuters)
EDITOR'S NOTE: Please check this post for updates during the day
1 Comment
On the other hand I think that there is little bang for the buck on publically reporting success on secondary endpoints. Raises more questions than answers. Makes me yearn for the days when we reported nary a single data point to the public until the NDA was approved, and sometimes even we didn't know when that would occur.